Sponsor Dossier
Novartis Pharmaceuticals
Sponsor Dossier for Novartis Pharmaceuticals. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ADAKVEO
- Brand: AFINITOR
- Brand: AIMOVIG
- Brand: AMLODIPINE/VALSARTAN NOVARTIS
- Brand: AMLODIPINE/VALSARTAN/HCT NOVARTIS
- Brand: ARTIGE
- Brand: ATECTURA BREEZHALER
- Brand: AVLOIRE
- Device (sponsor): Prefilled syringe/needle
- Device (sponsor): Surgical procedure kit, ophthalmic, medicated, single-use
About
Novartis Pharmaceuticals is an Australian Private Company with ABN 18 004 244 160, registered in NSW. The company is active and has been GST-registered since 2000.
Portfolio
Novartis Pharmaceuticals has 94 brands on the ARTG, with 84 indexable brands that have cleared the SEO quality gate. The portfolio includes 81 brands with Product Information on file, 35 brands with at least one PBS-listed item, 43 brands with PBAC outcomes on record, and 33 brands with AusPARs on record.
Therapeutic focus The portfolio spans the following therapeutic areas:
— Oncology: 19 brands — Neurology: 19 brands — Ophthalmology: 19 brands — Immunology: 10 brands — Cardiology: 9 brands — Respiratory: 7 brands — Infectious Disease: 5 brands — Haematology: 3 brands — Endocrinology: 2 brands — Rare Disease: 1 brand
PBS footprint
Novartis Pharmaceuticals has 35 brands with at least one PBS-listed item, with the portfolio most recently touching the PBS schedule on 1 May 2026.
Regulatory activity
The company's most recent PBAC outcome was received on 1 July 2025, with 43 brands holding PBAC outcomes on record. The most recent AusPAR was issued on 6 August 2024, with 33 brands holding AusPARs on record.